Table 1.
Demographics
| Transition | Control | P value | |
| n (%) or mean ± SD | n (%) or mean ± SD | ||
| Gender | |||
| Female | 23 (40.4) | 31 (56.4) | 0.13 |
| Diagnosis | |||
| CD | 47 (79.7) | 34 (64.2) | 0.07 |
| UC/IBDU | 12 (20.3) | 19 (35.8) | |
| Age (yr) | |||
| At diagnosis | 13.0 ± 2.9 | 13.0 ± 3.8 | 0.87 |
| Current | 19.7 ± 1.3 | 20.6 ± 1.2 | 0.0012 |
| Disease duration (yr) | 6.9 ± 3.2 | 7.6 ± 3.9 | 0.30 |
| Prior GI surgery | 13 (22.0) | 12 (21.8) | 0.98 |
| Medication1 | |||
| 5-ASA | 14 (25.0) | 20 (37.0) | 0.24 |
| IM | 17 (30.4) | 12 (22.2) | 0.33 |
| Anti-TNF | 6 (10.7) | 6 (11.1) | 1.00 |
| Combination | 13 (23.2) | 5 (9.3) | 0.07 |
| Any | 43 (76.8) | 37 (68.5) | 0.33 |
| Regular blood work | 45 (80.4) | 30 (55.6) | 0.012 |
1
Subgroups in medication row denote patients receiving oral 5-ASA products, IM only, anti-TNF only, combination therapy (IM and anti-TNF) only, or any IBD medication;
2
Statistically significant. 5-ASA: 5-aminosalicylic acid; anti-TNF: Anti-tumour necrosis factor agents including infliximab and adalimumab; CD: Crohn’s disease; IBDU: Inflammatory bowel disease unspecified; IM: Immunomodulators including methotrexate, 6-mercaptopurine, and azathioprine; UC: Ulcerative colitis.